Celyad Oncology SA American Depositary Shares
CYAD
CYAD was delisted on the 18th of May, 2023.
12 hedge funds and large institutions have $19.3M invested in Celyad Oncology SA American Depositary Shares in 2018 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 2 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
0% more funds holding
Funds holding: 12 → 12 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
9% less capital invested
Capital invested by funds: $21.4M → $19.3M (-$2.02M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.01M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$503K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$162K |
| 4 |
Morgan Stanley
New York
|
+$47.9K |
| 5 |
SLG
Stanley-Laman Group
Berwyn,
Pennsylvania
|
+$35.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EP
Eversept Partners
New York
|
-$382K |
| 2 |
Renaissance Technologies
New York
|
-$205K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$8.05K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$176 |
CYAD Hedge Fund Activity: Q3 2018 in Review
12 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Celyad Oncology SA American Depositary Shares (CYAD) for Q3 2018, worth a combined $19.3M — down 9.5% from $21.4M a quarter earlier.
Fund positioning in CYAD was balanced in Q3 2018: 2 funds opened new positions, 2 closed out, 5 added to existing stakes and 2 trimmed.
The largest buyer was Millennium Management, adding an estimated $1.01M. The largest seller was Eversept Partners, exiting entirely with an estimated $382K sold.
- 12 institutional investors held Celyad Oncology SA American Depositary Shares (CYAD) as of Q3 2018, unchanged from Q2 2018.
- Funds reported $19.3M of Celyad Oncology SA American Depositary Shares stock for Q3 2018, down 9.5% quarter-over-quarter.
- 2 funds opened new Celyad Oncology SA American Depositary Shares positions in Q3 2018 and 2 closed out, a net change of 0 holders.
- The largest Celyad Oncology SA American Depositary Shares buyer in Q3 2018 was Millennium Management, an estimated $1.01M added.
- The largest Celyad Oncology SA American Depositary Shares seller in Q3 2018 was Eversept Partners, an estimated $382K sold.
Based on aggregated 13F filings for Q3 2018.